• .

    .

    .
  • Amount requested $ * Est. Monthly Purchases $ *

  •  - -
  • Company Officers, Partners, Owners and / or Principals

    * ACCOUNT WILL NOT BE OPENED UNTIL BELOW SECTION IS COMPLETE *
  • Trade References

  • This application is submitted for the purpose of inducing Lifeline Pharmaceuticals LLC “The Medical Supply Depot” (LLPH) to extend credit to Applicant. The undersigned represent(s) that all information contained herein is true and correct and that (LLPH) may rely on said information in deciding whether to extend, decline or discontinue credit. The undersigned agree(s) to immediately notify (LLPH) in writing of any changes in the information provided, including but not limited to, any change in ownership, change of business name, change of business location or change in the financial condition of the business or the undersigned individual(s). The undersigned hereby authorize(s) (LLPH) to contact the above listed trade, banking references and / or run company or personal credit reports to verify the information listed above or determine credit worthiness. The undersigned agree(s) to release all persons and/or entities, including (LLPH), using or supplying the information from any claims and/or losses resulting there from. The undersigned agree(s) to pay all invoices in accordance with the agreed upon terms of the sale as printed on each invoice. The undersigned agrees to allow an ACH based on the check information provided for any payment by check. The undersigned proprietor(s), partner(s) and/or officer(s) of the Applicant, hereby agree to personally guarantee and assume all the obligations and responsibilities for any and all debts the Applicant shall incur in connection with the Applicant’s purchases from (LLPH) commencing on this date until such time as (LLPH) acknowledges the termination of said personal responsibility in writing. I/We have read and agree to all terms and conditions stated on this credit application.

     

    Additional Terms and Conditions of Service:
    These terms and conditions of service constitute a legally binding contract between LLPH and the Buyer. Buyer’s authorization for LLPH to provide service, whether verbal or written, shall constitute the Buyer’s agreement and consent to be bound by the terms and conditions set forth herein.
    Invoice & Payment Terms:
    The Buyer agrees to pay all invoices in accordance with the agreed upon terms of the sale as printed on each invoice. Buyer acknowledges that all invoices sent by LLPH shall be deemed true and correct unless the Buyer disputes the invoice, or any portion thereof, in writing within thirty (30) days of the date of the invoice. If only a portion of an invoice is disputed, Buyer shall remit the undisputed portion in accordance with the terms of the invoice and include an explanation of the dispute to facilitate resolution. Past due balances are subject to a service charge of 1.5% per month plus a $50.00 late fee per invoice, per 30 days (or the maximum amount permitted by law, if less). The undersigned agrees to allow an ACH based on the information provided on any payment by check. All payments are applied first to any service charge, the late fees and then to the oldest unpaid invoice. Buyer shall be responsible for payment of all costs incurred by LLPH to collect past due invoices, including without limitation, charge-back or returns fees $25, attorney’s fees, collection agency fees and court costs.

     

    Delivery:
    Delivery times and dates are approximate. In no event shall LLPH be liable for failure to perform, or a delay in performance, of any contract or supply any product due to 1) Acts of God, including but not limited to, inclement weather, flood, fire, power outages or natural disasters; 2) Insurrection, rebellion, civil war, terrorist action, revolution, riot, unrest, usurped power or any action taken by government or other authority in hindering, combating or defending against such occurrence; any seizure or destruction under quarantine or Customs regulations; confiscation by order of any government authority, or risk of contraband or illegal transportation or trade; 3) Strikes and labor disturbances; 4) Compliance with any law, statute, regulation, governmental order or requirements; 5) Manufacturer’s backorders, interruption in transportation, inability to obtain supplies at reasonable prices, shortage of raw materials, discontinuance of a product line, or other manufacturing problems; and 6) Any other cause beyond LLPH’s control. Transaction History, Information, and Statements are available to your facility for each prescription drug prior to the time of Delivery. Please visit us at www.lifelinepharm.com to download your transactional information. If you have any questions regarding transactional information, please call 305-643-8841 or email pedigrees@lifelinepharm.com.
    Returns:
    Merchandise may only be returned for an Exchange or Credit due to the following reasons: 1) merchandise is damaged, defective or in poor condition at time of delivery; or 2) incorrect merchandise or quantity is delivered. In order for a return to be processed, Buyer must notify LLPH within 24 hours of delivery and obtain a Return Merchandise Authorization (RMA) from LLPH prior to returning any merchandise. The merchandise and packaging must remain in the exact condition that existed at the time of the initial delivery in order for the return to be accepted. Pharmaceuticals cannot be returned. All credits will be purged after six months of not being used.
    Property:
    Title to the products purchased shall not pass to Buyer until such time as payment in full has been received by LLPH or Buyer’s account is in good standing.
    Partial Shipments:
    LLPH reserves the right to deliver partial shipments of any order and will maintain a backorder for the remaining quantity until available. Backorders may be cancelled by the Buyer at any time prior to shipment.
    Warranties:
    LLPH disclaims any and all representations and warranties, expressed or implied, including but not limited to any implied warranties or merchantability and fitness for a particular purpose in connection with this sale. Any and all warranties which may apply are provided by the manufacturers that LLPH represents as distributors. In no event shall LLPH be liable for any direct, indirect, incidental, consequential or punitive damages or any lost business, revenues or profits from any breach of this contract.
    Sales Tax:
    The sales tax in effect in Miami-Dade County, Florida at the time of purchase will be the sales tax charged on those items that are taxable.
    Change In Management/Control/Merger Of Buyer:
    Buyer shall inform LLPH within a period of at least thirty (30) days prior to the occurrence or effectively of a transfer of ownership (actual or beneficial) of the Buyer and/or change of management of the Buyer. In the event that Buyer, or substantially all of its assets or stock are sold, merged into or consolidated into a new entity, it is understood that the buying or surviving company and/or the new entity shall continue with this Agreement, and honor Buyer’s obligations hereunder, such that it were an original party hereto. Buyer shall ensure that the new owners and/or management shall honor this Agreement, including any and all obligations that have been incurred by the Buyer thereunder, under the same terms and conditions. In the alternative, LLPH shall have the right to require Buyer to liquidate all their outstanding obligations, regardless of the period previously granted, it being expressly understood by the Buyer that they will lose the right to avail of the period previously granted to pay such obligations in the event of a change of control and/or management, and/or merger and/or consolidation.
    Licensing and Regulatory Compliance:
    Buyer is responsible for submitting copies of renewed licenses or other written proof of continued validity of all permits, licenses or registrations associated
    with account to LLPH immediately upon receipt from issuing regulatory agency. Buyer shall immediately inform LLPH in writing of any change of status of all permits, licenses or registrations associated with account including but not limited to change of address, expiration, suspension, separation of licensee from Buyer, revocation, limitation of prior authorizations, relinquishment, etc. No Modification or Amendment Unless Written: These terms and conditions of service may only be modified, altered or amended in writing signed by both Buyer and LLPH; any attempt to unilaterally modify, alter or amend same shall be null and void.
    Severability:
    In the event any paragraph(s) and/or portion(s) hereof are found to be invalid and/or unenforceable, then in such event the remainder hereof shall remain in
    full force and effect.
    Consent to Jurisdiction and Venue; Governing Law:
    Each party agrees to personal jurisdiction in any action brought in any court, Federal or State, within the County of Miami-Dade, State of Florida, having subject matter jurisdiction over the matters arising under this Agreement. Any suit, action or proceeding arising out of or relating to this Agreement shall only be instituted in the County of Miami-Dade, State of Florida. Each party waives any objection which it may have now or hereafter to the laying of the venue of such action or proceeding and irrevocably submits to the jurisdiction of any such court in any such suit, action or proceeding. All matters arising under this Agreement shall be governed by Florida law unless Federal law is applicable.

  • Please attach following files below.

    1. Copy of your Clinical/facility license.
    2. Copy of the Doctor's or Medical Director's medical license.
    3. Copy of your DEA license.
    4. Copy of your State Controlled Medications license, if any.
  • Browse Files
    Drag and drop files here
    Choose a file
    Cancelof
  •  - -
  • Clear
  • Bank Reference Request

  • The company below has given Lifeline Pharmaceuticals, LLC the permission to request a bank reference, this request is limited to length of time account has been open, average balance, and any pertinent derogatory information within the request account. (NFS, Charges, Late fees ...)

  • The above stated company gives Lifeline Pharmaceuticals, LLC permission to receive the agreed bank reference information.

  •  - -
  • Clear
  • Dear Bank Officer,
    We are requesting a Bank reference for the above stated Company and would appreciate a prompt response via fax # 305-643-6929 or email accounting@lifelinepharm.com.


    PLEASE BE ASSURED ALL INFORMATION PROVIDED WILL BE KEPT CONFIDENTIAL

  •  - -
  • Average balance on the last 6 month period $

  • # of times      

  • Clear
  • PLEASE COMPLETE EITHER 1.) ELECTRONIC FUNDS TRANSFER OR 2.) CREDIT CARD AUTHORIZATION BELOW

  •                         1.) Electronic Funds Transfer Authorization
    I hereby authorize Lifeline Pharmaceuticals to use the Cash Management System that the Company accesses throught its bank account to electronically send requests for funds transfers through the Automatic Clearing House from my account.

  • Browse Files
    Drag and drop files here
    Choose a file
    Cancelof
  • Clear
  •                               Controlled Substance Order Monitoring Program

              Title 21 Code of Federal Regulations Part 1301 Section 1301.74

     

    One of the top priorities of Lifeline Pharmaceuticals is to prevent diversion and abuse of controlled substances. It is a federal mandate that all distributors of controlled substances "design and operate a system to disclose to the registrant suspicious orders for controlled substances." The DEA defines a suspicious order as an order of unusual size, orders deviating substantially from a normal pattern, and orders of unusual frequency.

    In response to the DEA requirement, Lifeline Pharmaceuticals, LLC has implemented an Order Monitoring Program that provides effective controls to detect and prevent diversion. Under this program, we will use a set of rules and a review of customer purchase history and submitted compliance documents. If the program finds any anomalies in the order, the order is flagged and held for review by our Compliance Team. We will continuously modify and enhance the program to ensure compliance with DEA regulations while providing exceptional customer service.

    Title 21 Code of Federal Regulations Part 1301 Section 1301.74 can be viewed in its entirety at http://www.deadiversion.usdoj.gov/21cfr/cft/1301/1301_74.htm.

    Below are excerpts from the regulation that relate directly to the Suspicious Order Monitoring requirements.

    1. Before distributing a controlled substance to any person who the registrant does not know to be registered to possess the controlled substance, the registrant shall make a good faith inquiry either with the Administration or with the appropriate State controlled substances registration agency, if any, to determine that the person is registered to possess the controlled substance.
    2. The registrant shall design and operate a system to disclose to the registrant suspicious orders of controlled substances. The registrant shall inform the Field Division Office of the Administration in his area of suspicious orders when discovered by the registrant. Suspicious orders include orders of unusual size, orders deviating substantially from a normal pattern, and orders of unusual frequency.
    3. The registrant shall notify the Field Division Office of the Administration in his area, in writing, of any theft or significant toss of any controlled substances within one business day of discovery of the theft or loss. The supplier is responsible for reporting all in-transit losses of controlled substances by the common or contract carrier selected pursuant to paragraph (e) of this section, within one business day of discovery of such theft or loss. The registrant shall also complete and submit to the Field Division Office in his area, DEA Form 106 regarding theft or loss. Thefts and significant losses must be reported whether or not the controlled substances are subsequently recovered, or the responsible parties are identified, and action taken against them. When determining whether a loss is significant, a registrant should consider, among others, the following factors:
    1. The actual quantity of controlled substances lost in relation to the type of business.
    2. The specific controlled substances lost.
    3. Whether the loss of the controlled substances can be associated with access to those controlled substances by specific individuals, or whether the loss can be attributed to unique activities that may take place involving the controlled substance.
    4. A pattern of losses over a specific time period, whether the losses appear to be random, and the results of efforts taken to resolve the losses; and, if known, whether the specific controlled substances are likely candidates for diversion.
    5. Local trends and other indicators of the diversion potential of the missing controlled substance

     

    DEA "Know Your Customer" Policy

    In addition to the requirements listed in Title 21 Code of Federal Regulations Part 1301 Section 1301.74, all distributors of schedule II-V controlled substances and list I chemicals are required by the DEA to comply with the "Know Your Customer" Policy. Per the DEA "Know Your Customer" Policy, “It is fundamental for sound operations that handlers take reasonable measures to identify their customers, understand the normal and expected transactions typically conducted by those customers, and, consequently, identify those transactions conducted by their customers that are suspicious in nature.”

    In order to assist us in complying with the "Know Your Customer" Policy, the DEA published a list of 48 suggested questions that we should ask our customers prior to shipping controlled substances to them. These questions were used to help Lifeline Pharmaceuticals, LLC develop the questionnaires and lists of required documents used in our "Know Your Customer" Policy.

    Please assist us in complying with these DEA requirements by completing the requested questionnaire thoroughly with all applicable details and submitting all requested documentation. Additionally, we ask that you cooperate with any on-site inspections or telephone interviews.

    If you have questions or concerns, please feel free to contact Ms. Vanessa Santodomingo or Ms. Erika Reyna at (305) 643-8841 or (877) 430-6337.

    Respectfully,

     

      

    Richard O. Mitchell

    Chief Compliance Officer

     

  • Controlled Substance Customer Questionnaire and Declaration

    Please answer ALL applicable questions
  •  - -
  • General information and Licensing

  • In the case where the Registration is in the business name, we would need a copy of the DEA Registration Receipt which shows who the Registrant for the facility is. Please follow the instructions below and provide us with a copy of the receipt once you get it. Additionally, if you have a Power of Attorney associated with the DEA Registration, please also provide us a copy.
     
     
    https://apps.deadiversion.usdoj.gov/webforms2/spring/login?execution=e2s1
     
    Choose option # 6 for registration receipt

  • Browse Files
    Drag and drop files here
    Choose a file
    Cancelof
  • Ownership / Business History

  • Business Information

  • 3) If a physician practice/clinic, how is business received? (Please list percent):
    Walk-in* %. Appointment * %

  • 5) What is the average distance that your patients travel to reach your facility? *Miles

  • 6) What is the longest distance for a patient to travel? *Miles

  • 7) What is the average number of patients per day per doctor?*

  • Browse Files
    Drag and drop files here
    Choose a file
    Cancelof
  • If yes, what is the percentage of the patient total? %

  • Browse Files
    Drag and drop files here
    Choose a file
    Cancelof
  • Purchasing Information

  • 1) Total estimated monthly purchases of all items (i.e. Devices, OTC Products, and Supplies) $ *

  • 2) Total estimated monthly Rx drug purchases (including controlled substances): $ *

  • 3) Purchase breakdown:
    a. Rx Drugs*%
    b. Controlled Substances   *   %
    c. All Other Items   *   %

  • 4) Number of prescriptions filled per day*/ per month  *   

  • 5) Method of payment by your patients/customers:
    Private insurance:*% Medicare/Medicaid: *%
    Cash:*% Credit Card:*%
    Other:   *%

  • Controlled Substance Purchases

  • Required Documentation
    1.) Completed questionnaire affidavit.
    2.) DEA and State Controlled Substance Registration.
    3.) Any Letters of Admonition, Orders to Show Cause or Memorandum of Agreement with the DEA that are
    currently in effect or issued in the previous 5 years. Include any responses to these letters/documents.
    4.) Disciplinary documents from local, state or federal agencies.
    5.) Copies of all DEA Form 106 submitted to the DEA in the prior 36 months.
    6.) Customer marketing materials and website Information.
    7.) Most recent 90 days controlled substance dispensing records.
    8.) Most recent 30 days controlled substance purchasing records.
    9.) Photographs of the interior and exterior of the facility and security features to include photo of Narcotic cabinet/safe open and closed.
    10.) Copies of any Power of Attorney documents in effect over the DEA Controlled Substance Registration.

     

    Please answer each question completely and include all supporting documentation that may assist us in determining your eligibility to purchase controlled substances and the proper allocations necessary to best serve your facilities within the limits of all applicable laws (i.e., licenses, questionnaires, inspection reports, policy and procedures, etc.). Your failure to do so will delay our approval process.

  • Browse Files
    Drag and drop files here
    Choose a file
    Cancelof
  • Estimated doses (tablets/capsules) administered per month, for each of the following List I Chemicals.

    Ephedrine Quantity Per Month:
    Pseudoephedrine(PSE) Quantity Per Month:
    Guaifenesin/PSE Quantity Per Month:    
    Lugol's Iodine Quantity Per Month:    

  • Estimated vials of Testosterone purchased per month to be administered in office.
    Testosterone Quantity Per Month:

  • Clear
  • DECLARATIONS/AFFIDAVIT OF APPLICANT(S)
    (The person completing this form and the Medical Director or Owner must initial and sign this page)

    I hereby attest that I am an authorized representative of the below-listed facility and have the authority to bind the facility to the terms of this affidavit. I further attest that all the statements of fact are true and accurate to the best of my knowledge and certify that I have made sufficient inquiry to be able to make this declaration.
    Initial   *  

    I declare that this facility fully complies with all federal, state and local laws and regulations on the dispensing and administration of controlled substances.
    Initial   *   

    I hereby attest that this facility or any of the owners, management, staff or its contractors have not been issued any warning notice, notice of violation and are not knowingly under investigation by any regulatory authority. I further agree to notify Lifeline Pharmaceuticals within 5 business days of any warning notice, notice of violation or investigative proceedings by any regulatory authority issued upon this facility or any of the owners, management, staff or its contractors.
    Initial   *   

    By executing this affidavit, this facility and all representatives agree that all controlled substances distributed to this facility by Lifeline Pharmaceuticals, LLC, shall only be dispensed / administered at the address of record and shall not be dispensed, sold or transferred off-site. Initial   *   

    By executing this affidavit, this facility and all representatives agree to inform Lifeline Pharmaceuticals, LLC in writing, within 5 business days of any changes affecting ownership, physical location, license status, and/or key employees including but not limited to: Medical Director, Buyer, Pharmacy Manager, and Staff Doctors.
    *   

  • Clear
  • Clear
  • Should be Empty: